Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 21220594

Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2011 Mar 1
First author
Verstovsek S

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021.
    note
    Source null
    related pmid
    21220608
    relationship
    Comment on

Authors and identifiers

  1. name
    Verstovsek S
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Verstovsek S
    type
    Author
bibliography ids
  1. nci-bib-fbb487bcecb5e8ef91dac810
book metadata
content sha256
90e53881dd651d35c85e3564231bb1cd089a4ae0f574c4b7b94e16bc89f92ee2
document type
citation
dois
  1. 10.1200/JCO.2010.33.4508
electronic publication date
display
2011 Jan 10
precision
day
year
2011
evidence scope
bibliographic_metadata_only
id
pubmed:21220594
immutable id
pubmed:21220594@90e53881dd651d35c85e3564231bb1cd089a4ae0f574c4b7b94e16bc89f92ee2
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
7
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
781-3
volume
29
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2011 Mar 1;29(7):789-96. doi: 10.1200/JCO.2010.32.8021.
    note
    Source null
    related pmid
    21220608
    relationship
    Comment on
outcomes validated
false
pmid
21220594
provenance
batch id
edef4b7f1a2a505cd5a9
provider
NCBI PubMed ESummary
record sha256
789818fb7f48ef8cdb636a1a33646de04f0a51b5db82240dc1df6da3e5f3c0eb
response sha256
d2d0fd7c34783716c953156f8a1da1b7b36c4823b416656eca04a1e69e03a295
retrieved at
2026-09-09T23:46:38.027615+00:00
publication date
display
2011 Mar 1
precision
day
year
2011
publication types
  1. Comment
  2. Editorial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/21220594/
title
Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms.

Preserved source evidence · Not medical advice